A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
PHARMING GROUP operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 297M | 297M | 245M | 206M | 199M | 212M |
| Net Income | -12M | -12M | -11M | 14M | 16M | 38M |
| EPS | $-0.02 | $-0.02 | $-0.02 | $0.02 | $0.02 | $0.06 |
| Free Cash Flow | -2.6M | -2.6M | -19M | 21M | 27M | 79M |
| ROIC | -4.1% | -2.2% | -1.7% | 8.5% | 6.8% | 41.5% |
| Gross Margin | 88.1% | 88.1% | 89.7% | 91.5% | 89.4% | 88.9% |
| Debt/Equity | 0.00 | 0.48 | 0.76 | 0.79 | 0.82 | 0.86 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.6M | -8.6M | -5.4M | 18M | 14M | 76M |
| Operating Margin | -2.9% | -2.9% | -2.2% | 8.9% | 6.8% | 35.9% |
| ROE | -5.4% | -5.4% | -5.0% | 6.9% | 8.5% | 20.6% |
| Shares Outstanding | 658M | 658M | 659M | 651M | 640M | 651M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 212M | 199M | 206M | 245M | 297M | 297M |
| Gross Margin | 88.9% | 89.4% | 91.5% | 89.7% | 88.1% | 88.1% |
| R&D | -39M | -70M | -53M | -69M | -83M | -83M |
| SG&A | 151M | N/A | N/A | N/A | N/A | N/A |
| EBIT | 76M | 14M | 18M | -5.4M | -8.6M | -8.6M |
| Op. Margin | 35.9% | 6.8% | 8.9% | -2.2% | -2.9% | -2.9% |
| Net Income | 38M | 16M | 14M | -11M | -12M | -12M |
| Net Margin | 17.8% | 8.0% | 6.7% | -4.3% | -4.0% | -4.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 41.5% | 6.8% | 8.5% | -1.7% | -2.2% | -4.1% |
| ROE | 20.6% | 8.5% | 6.9% | -5.0% | -5.4% | -5.4% |
| ROA | 9.0% | 3.9% | 3.3% | -2.4% | -2.7% | -3.0% |
| Cash Flow | ||||||
| Op. Cash Flow | 84M | 38M | 22M | -17M | -1.8M | -1.8M |
| Free Cash Flow | 79M | 27M | 21M | -19M | -2.6M | -2.6M |
| Owner Earnings | 69M | 9.2M | 2.9M | -42M | -29M | -29M |
| CapEx | 4.7M | 11M | 1.4M | 1.4M | 790K | 790K |
| Maint. CapEx | 8.3M | 20M | 13M | 16M | 16M | 16M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 8.3M | 20M | 13M | 16M | 16M | 16M |
| CapEx/OCF | 5.6% | 28.4% | 6.1% | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 6.5M | 9.1M | 6.4M | 9.3M | 11M | 11M |
| Debt Repayment | 57M | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -47M | -34M | -46M | 104M | 50M | -55M |
| Cash & Equiv. | 205M | 192M | 207M | 62M | 55M | 55M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.86 | 0.82 | 0.79 | 0.76 | 0.48 | 0.00 |
| Interest Coverage | 2.3 | 2.2 | 3.3 | -0.6 | -0.9 | -0.9 |
| Equity | 183M | 193M | 205M | 219M | 221M | 221M |
| Total Assets | 418M | 397M | 426M | 463M | 400M | 400M |
| Total Liabilities | 235M | 204M | 221M | 244M | 179M | 179M |
| Intangibles | N/A | N/A | N/A | 71M | 61M | 61M |
| Retained Earnings | -296M | -273M | -256M | -265M | -275M | -275M |
| Working Capital | 186M | 203M | 218M | 238M | 205M | 205M |
| Current Assets | 263M | 249M | 278M | 316M | 278M | 278M |
| Current Liabilities | 77M | 47M | 60M | 78M | 74M | 74M |
| Per Share Data | ||||||
| EPS | 0.06 | 0.02 | 0.02 | -0.02 | -0.02 | -0.02 |
| Owner EPS | 0.11 | 0.01 | 0.00 | -0.06 | -0.04 | -0.04 |
| Book Value | 0.28 | 0.30 | 0.31 | 0.33 | 0.34 | 0.34 |
| Cash Flow/Share | 0.13 | 0.06 | 0.03 | -0.03 | -0.00 | 0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 650.8M | 639.8M | 651.1M | 659.3M | 657.8M | 657.8M |
| Valuation | ||||||
| P/E Ratio | 24.4 | 32.3 | 56.5 | -64.4 | -52.6 | -80.7 |
| P/FCF | 11.1 | 17.6 | 33.1 | N/A | N/A | N/A |
| EV/EBIT | 10.8 | 32.6 | 35.8 | N/A | N/A | N/A |
| Price/Book | 4.8 | 2.5 | 3.4 | 3.1 | 2.8 | 4.3 |
| Price/Sales | 4.1 | 2.4 | 3.4 | 2.8 | 2.1 | 3.2 |
| FCF Yield | 9.0% | 5.7% | 3.0% | -2.8% | -0.4% | -0.3% |
| Market Cap | 874M | 476M | 699M | 680M | 623M | 956M |
| Avg. Price | 1.15 | 0.97 | 0.90 | 1.11 | 0.86 | 1.45 |
| Year-End Price | 1.34 | 0.74 | 1.07 | 1.03 | 0.95 | 1.45 |
PHARMING GROUP passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 10.6% with a gross margin of 89.5%. At current prices, the estimated annualized return to fair value is -34.2%.
PHARMING GROUP (PHARM-AS) has a 5-year average return on invested capital (ROIC) of 10.6%. This indicates solid capital allocation.
PHARMING GROUP (PHARM-AS) has a market capitalization of $956M. It is classified as a small-cap stock.
PHARMING GROUP (PHARM-AS) does not currently pay a regular dividend.
PHARMING GROUP (PHARM-AS) operates in the Biotechnology industry, within the Healthcare sector.
PHARMING GROUP (PHARM-AS) reported annual revenue of $297 million in its most recent fiscal year, based on SEC EDGAR filings.
PHARMING GROUP (PHARM-AS) has a net profit margin of -4.0%. The company is currently unprofitable.
PHARMING GROUP (PHARM-AS) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PHARMING GROUP (PHARM-AS) has a debt-to-equity ratio of 0.48. This indicates a conservatively financed balance sheet.
PHARMING GROUP (PHARM-AS) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
PHARMING GROUP (PHARM-AS) has a return on equity (ROE) of -5.4%. A negative ROE may indicate losses or negative equity.
PHARMING GROUP (PHARM-AS) has a 5-year average gross margin of 89.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for PHARMING GROUP (PHARM-AS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PHARMING GROUP (PHARM-AS) has a book value per share of $0.34, based on its most recent annual SEC filing.